Glancy Binkow & Goldberg LLP reminds investors of OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ:OVAS) that all purchasers of the Company’s common stock between February 25, 2013 and September 10, 2013, inclusive (the “Class Period”), have until August 5, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
OvaScience is engaged in the discovery, development and commercialization of new treatments for infertility. The Company’s first fertility treatment is AUGMENT – an assisted reproductive technology which complements the existing standard of practice for an in vitro fertilization cycle. The Complaint alleges that the Company misrepresented or failed to disclose material information concerning the clinical development of AUGMENT and regulatory concerns raised by the Food and Drug Administration that could potentially threaten or delay FDA approval of AUGMENT.
On September 10, 2013, OvaScience disclosed that it was suspending enrollment of the AUGMENT clinical trial in the United States, after the Company received a letter from the FDA questioning whether AUGMENT qualified for reduced regulatory oversight and advising the Company to file an Investigational New Drug application. Following this news, OvaSceince shares dropped more than 23%, or $3.32 per share, to close at $10.95 per share on September 11, 2013.
If you are a member of the Class described above, you may move the Court no later than August 5, 2014, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.